IRIS Institutional Research Information System - OPENBS Open Archive UniBS

ODICINO, Franco Edoardo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.103
EU - Europa 6.103
AS - Asia 5.688
SA - Sud America 928
Continente sconosciuto - Info sul continente non disponibili 498
AF - Africa 165
OC - Oceania 80
AN - Antartide 1
Totale 25.566
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.653
IT - Italia 2.525
SG - Singapore 1.866
CN - Cina 1.534
BR - Brasile 746
UA - Ucraina 655
HK - Hong Kong 602
DE - Germania 505
PL - Polonia 504
BD - Bangladesh 493
GB - Regno Unito 388
VN - Vietnam 319
FI - Finlandia 298
FR - Francia 272
CA - Canada 239
TR - Turchia 215
RU - Federazione Russa 192
IN - India 189
IE - Irlanda 151
CH - Svizzera 146
ES - Italia 92
ID - Indonesia 88
MX - Messico 72
NL - Olanda 69
SE - Svezia 69
AU - Australia 64
AR - Argentina 63
JP - Giappone 62
IQ - Iraq 55
EE - Estonia 53
ZA - Sudafrica 53
SA - Arabia Saudita 42
EC - Ecuador 29
MY - Malesia 26
CR - Costa Rica 24
PH - Filippine 23
CO - Colombia 22
AT - Austria 20
CZ - Repubblica Ceca 20
LT - Lituania 20
MA - Marocco 20
HN - Honduras 19
JM - Giamaica 19
PK - Pakistan 19
UZ - Uzbekistan 18
CL - Cile 17
BE - Belgio 16
PE - Perù 15
PT - Portogallo 15
JO - Giordania 14
NZ - Nuova Zelanda 14
VE - Venezuela 14
AE - Emirati Arabi Uniti 13
EG - Egitto 13
KE - Kenya 13
LI - Liechtenstein 13
GT - Guatemala 12
IL - Israele 12
SV - El Salvador 12
DZ - Algeria 11
NP - Nepal 11
TT - Trinidad e Tobago 11
AZ - Azerbaigian 10
LU - Lussemburgo 10
BG - Bulgaria 9
BO - Bolivia 9
CW - ???statistics.table.value.countryCode.CW??? 9
SK - Slovacchia (Repubblica Slovacca) 9
TN - Tunisia 9
KR - Corea 8
KZ - Kazakistan 8
NI - Nicaragua 8
PY - Paraguay 8
AL - Albania 7
DK - Danimarca 7
ET - Etiopia 7
MK - Macedonia 7
OM - Oman 7
TH - Thailandia 7
BH - Bahrain 6
GP - Guadalupe 6
IR - Iran 6
NG - Nigeria 6
UG - Uganda 6
BB - Barbados 5
EU - Europa 5
GH - Ghana 5
GR - Grecia 5
KG - Kirghizistan 5
UY - Uruguay 5
BS - Bahamas 4
KW - Kuwait 4
LK - Sri Lanka 4
LV - Lettonia 4
MU - Mauritius 4
PR - Porto Rico 4
PS - Palestinian Territory 4
RO - Romania 4
RS - Serbia 4
SC - Seychelles 4
Totale 25.018
Salva come PNG Salva come JPEG
Città #
Ashburn 1.253
Singapore 953
Fairfield 913
Woodbridge 769
San Jose 708
Hong Kong 593
Houston 494
Warsaw 485
Jacksonville 446
New York 396
Seattle 389
Wilmington 385
Council Bluffs 356
Chandler 344
Beijing 341
Ann Arbor 338
Cambridge 328
Los Angeles 284
The Dalles 255
Princeton 239
Milan 222
Brescia 170
Dearborn 169
Helsinki 165
Nanjing 158
Lauterbourg 149
Dublin 148
Istanbul 141
Santa Clara 129
Dallas 126
Munich 122
Ho Chi Minh City 115
Rome 114
Chicago 104
London 103
Buffalo 99
Des Moines 99
Columbus 90
Zurich 90
Moscow 89
San Francisco 89
São Paulo 84
Boardman 70
Redondo Beach 70
Toronto 68
Shanghai 67
Hanoi 64
Shenyang 51
Nanchang 49
Tallinn 49
Jakarta 47
Denver 44
Orem 44
Changsha 43
San Diego 43
Hangzhou 42
Montreal 42
Tokyo 41
Frankfurt am Main 40
Hebei 40
North Bergen 40
Chennai 38
Phoenix 38
Tianjin 36
Stockholm 34
Brooklyn 33
Charlotte 33
Turku 33
Jinan 32
Johannesburg 31
Nuremberg 30
Guangzhou 29
Jiaxing 29
Naples 29
Poplar 28
Turin 28
Melbourne 27
Boston 26
Atlanta 25
Kunming 25
Paris 24
Washington 24
Mexico City 23
Bologna 21
Dhaka 21
Romola 21
Dong Ket 20
Manchester 20
Pune 20
San José 20
Verona 20
Genoa 19
Lappeenranta 19
Ankara 18
Baghdad 18
Belo Horizonte 18
Brasília 18
Mumbai 18
Philadelphia 18
Florence 16
Totale 14.978
Salva come PNG Salva come JPEG
Nome #
Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study 3.100
Preeclampsia and late fetal growth restriction 426
Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues 373
Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. 344
Claudin3 is localized outside the tight junctions in human carcinomas 305
Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery 302
Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients. 227
Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. 216
Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts 216
FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients 212
Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. 199
Female Adnexal Tumor of Probable Wolffian Origin (FATWO): Case Report and Systematic Literature Review 192
Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum 192
Role of 18F-FDG PET/CT in restaging and follow-up of patients with uterine sarcomas 186
RERT: A Novel Regression Tree Approach to Predict Extrauterine Disease in Endometrial Carcinoma Patients 185
Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence 184
Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. 183
Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum 183
MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis 183
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition 180
Trefoil factor 3: a novel serum marker identified by gene expression profiling in highgrade endometrial carcinomas 177
Consolidation therapies revisited: weekly paclitaxel 177
Carcinoma of the Fallopian tube 170
Clear cell degeneration associated with endometriosis of abdominal wall after cesarean section: A case report and systematic review of literature 170
Clinical and prognostic value of 18 F-FDG PET/CT in recurrent endometrial carcinoma 169
Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study 166
Carcinoma of the corpus uteri 161
Claudin 7 downregulation is predictive of distant metastasis in high-grade serous carcinoma patients 160
The claudin-low subtype of high-grade serous ovarian carcinoma exhibits stem cell features 160
Treatment of Early Cesarean Scar Pregnancy with Double Balloon Catheter: A Systematic Review of the Literature 159
The HIV-protease inhibitor saquinavir reduces proliferation, invasion and clonogenicity in cervical cancer cell lines 158
Improved Risk Prediction in Human Papillomavirus-Associated Endocervical Adenocarcinoma Through Assessment of Binary Silva Pattern-based Classification: An International Multicenter Retrospective Observational Study Led by the International Society of Gynecological Pathologists (ISGyP) 156
Carcinoma of the Fallopian tube 156
Adjuvant cisplatin-based chemotherapy for stage I and II ovarian cancer: a 7-year experience 155
Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome 155
Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers 154
Role of HPV DNA, HPV mRNA and cytology in the follow-up of women treated for cervical dysplasia. 153
Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients. 152
Low Expression of Claudin-7 as Potential Predictor of Distant Metastases in High-Grade Serous Ovarian Carcinoma Patients 152
Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer 151
Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro 150
Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium 149
Replacement therapy for breast cancer survivors. A pilot study 149
Early stage ovarian cancer: the Italian contribution to clinical research. An update 149
Parametrial endometriosis with ureteral involvement: A case report of a conservative approach without ureteral resection 148
Staging classification for cancer of the ovary, fallopian tube, and peritoneum 147
Hysteroscopic removal of a retained intrauterine foreign body: a step-by-step technique 146
Carcinoma of the corpus uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. 145
Morphologic and biologic studies on ten cases of verrucous carcinoma of the vulva supporting the theory of a discrete clinico-pathologic entity 145
Carcinoma of the corpus uteri 145
New development of the FIGO staging system. 144
Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. 143
Parametrial endometriosis with ureteral involvement: A case report of a conservative approach without ureteral resection 143
Death following pulmonary complications of surgery before and during the SARS-CoV-2 pandemic 143
LncRNAs as novel indicators of patients' prognosis in stage i epithelial ovarian cancer: A retrospective and multicentric study 142
Prognostic role of immunohistochemical and molecular markers in no specific molecular profile endometrial cancer: a systematic review and meta-analysis 141
Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study 141
Carcinoma of the fallopian tube. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. 140
Interval debulking surgery in advanced epithelial ovarian cancer 140
Gestational trophoblastic diseases 140
Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer 140
Early non-compliance to ERAS in gynecological open surgery for malignancies, and post-operative complications: a multicenter, prospective, observational, cohort study 139
Five-year follow-up of placental involution after abdominal pregnancy 139
History of the FIGO cancer staging system 137
Management of endometrial cancer in Italy: a national survey endorsed by the Italian Society of Gynecologic Oncology 137
Carcinoma of the ovary 135
Systemic therapy for gynecological neoplasms: ovary, cervix and endometrium 135
Staging of gynecologic malignancies 135
Revised FIGO staging for carcinoma of the cervix. 134
Carcinoma of the ovary 134
Gestational trophoblastic diseases 133
Hormone replacement therapy in breast cancer 133
Real World Application of Chemotherapy Response Score in High Grade Serous Cancer of the Ovary 133
Ultrasound examination in ovarian cancer patients. A comparison with second look laparotomy 132
Carcinoma of the cervix uteri 132
null 132
Chronic hypertension in pregnancy: insights into adverse outcomes prevention 131
Systemic therapy for gynecological neoplasms: ovary, cervix, and endometrium. 130
Pre-treatment Serum HE4 Level as a Novel Independent Prognostic Biomarker for Uterine Cervical Carcinoma Patients 130
Uterine sarcomas: a clinicopathologic study 129
Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study 129
Carcinoma of the cervix uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. 128
Randomized study comparing chemotherapy plus radiotherapy versus radiotherapy alone in FIGO stage IIB-III cervical carcinoma. GONO (North-West Oncologic Cooperative Group) 127
Carcinoma of the cervix uteri 127
FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients 127
Optimizing gemcitabine regimens in ovarian cancer. 126
Recurrent ovarian carcinoma: salvage treatment with platinum in patients responding to first-line platinum-based regimens 126
Cold Knife Versus Carbon Dioxide for the Treatment of Preinvasive Cervical Lesion 125
Integrated mutational landscape analysis of uterine leiomyosarcomas 125
Carcinoma of the vagina 125
Ovarial cancer: best timing and applications of debulking surgery 124
Cancer in women 124
Clinical features and surgical options of obstructed hemivagina and ipsilateral renal agenesis (OHVIRA) syndrome: A systematic review and a meta-analysis of prevalence 123
Long-term therapy with dienogest or other oral cyclic estrogen-progestogen can reduce the need for ovarian endometrioma surgery 123
Which second-line treatment regimen should be used following relapse of platinum-sensitive ovarian cancer? 123
Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology. 123
Crossover study with cisplatin or carboplatin in advanced ovarian cancer 123
Elective Cancer Surgery in COVID-19-Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study 122
Delaying surgery for patients with a previous SARS-CoV-2 infection 122
Integrated Biomarker Analysis Reveals L1CAM as a Potential Stratification Marker for No Specific Molecular Profile High-Risk Endometrial Carcinoma 121
Totale 18.862
Salva come PNG Salva come JPEG
Categoria #
all - tutte 113.738
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 113.738
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022791 0 0 0 43 3 51 105 70 48 122 96 253
2022/20232.139 159 59 207 274 229 283 67 148 193 128 211 181
2023/20242.370 177 106 201 159 209 375 137 183 361 245 45 172
2024/20253.500 41 109 93 465 302 309 321 142 386 250 650 432
2025/20267.248 676 825 442 819 724 463 1.070 343 419 623 446 398
2026/20272.481 373 456 613 1.039 0 0 0 0 0 0 0 0
Totale 25.566